摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-溴-2(1H)-喹喔啉酮 | 82031-32-1

中文名称
7-溴-2(1H)-喹喔啉酮
中文别名
——
英文名称
7-bromo-1H-quinoxalin-2-one
英文别名
7-bromoquinoxalin-2(1H)-one;7-bromo-2(1H)-quinoxalinone;7-bromoquinoxalin-2-ol
7-溴-2(1H)-喹喔啉酮化学式
CAS
82031-32-1
化学式
C8H5BrN2O
mdl
MFCD01465145
分子量
225.044
InChiKey
PXVQWJPOMIRXQL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.82±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    41.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P280,P305+P351+P338,P310
  • 危险性描述:
    H302,H315,H319,H332,H335

SDS

SDS:ea018f95def21aec29e6efe7f2fea53d
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 7-Bromoquinoxalin-2(1h)-one
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromoquinoxalin-2(1h)-one
CAS number: 82031-32-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5BrN2O
Molecular weight: 225.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

7-溴-2(1H)-喹喔啉酮是一种常用的喹诺酮类医药中间体,可通过邻苯二胺乙二酸乙二酯制备得到喹诺酮中间体,再进行代反应。

应用

7-溴-2(1H)-喹喔啉酮主要用于有机合成及医药中间体领域,在实验室研发过程和化工医药合成过程中均有广泛应用。

制备 第一步:合成喹诺酮中间体

将200克(1.85 mol)邻苯二胺溶解在1.2升乙醇中。逐滴加入450毫升(50%甲苯溶液)的乙二酸乙二酯,然后加热至50℃反应12小时,冷却至5℃保持1小时。过滤混合物,并用洗涤固体产物,以邻苯二胺为基准计算收率为92%。

第二步:制备7-溴-2(1H)-喹喔啉酮

将250克(1.7 mol)的喹诺酮溶解在4500毫升乙酸中。逐滴加入乙酸(988 mL)和(108 mL,2.1 mol)的混合物,并在室温下搅拌反应12小时,然后加热至60℃保持12小时。冷却后过滤固体产物,并用洗涤湿饼。将湿饼溶解于1500毫升甲醇中,加热至60℃后再进行过滤并干燥,在此步骤中的收率为85%。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-溴-2(1H)-喹喔啉酮 在 palladium diacetate 、 sodium carbonatecaesium carbonate三苯基膦4,5-双二苯基膦-9,9-二甲基氧杂蒽三氯氧磷 作用下, 以 1,4-二氧六环甲苯 为溶剂, 反应 34.0h, 生成 厄达替尼
    参考文献:
    名称:
    erdafitinib 的新型聚合合成
    摘要:
    从市售化学品 quinoxalin-2-ol、4-bromo-1-methyl-1 H -pyrazole 和 2-bromo-1,1-开发了 20 g 规模的 erdafitinib 的新聚合合成路线二甲氧基乙烷。关键中间体 3,5-二甲氧基苯基-异丙基乙烷-1,2-二胺 ( 17 ) 由 2-溴-1,1-二甲氧基乙烷制备,两步收率为 89%,纯度为 98.8%。Erdafitinib 是从 7-bromo-2-(1-methyl- 1H -pyrazol -4-yl) quinoxaline ( 8 ) 和17中获得的,产率为 89%,纯度为 99.4%。该收敛合成路线共有7步,总收率为54%。
    DOI:
    10.1002/jhet.4544
  • 作为产物:
    描述:
    邻苯二胺溶剂黄146 作用下, 以 乙醇 为溶剂, 反应 2.5h, 生成 7-溴-2(1H)-喹喔啉酮
    参考文献:
    名称:
    [EN] COMBINATION OF KINASE INHIBITORS AND USES THEREOF
    [FR] COMBINAISON D'INHIBITEURS DE KINASE ET SES UTILISATIONS
    摘要:
    本发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。另一方面,该发明提供了一种治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的方法。在另一个方面,提出了一种抑制细胞内Akt(S473)和Akt(T308)磷酸化的方法。本发明还提供了一种有效治疗与受体内PI3-激酶α和/或mTOR相关的疾病状况的药物套装。
    公开号:
    WO2014151147A1
点击查看最新优质反应信息

文献信息

  • [EN] ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES<br/>[FR] BENZOPYRAZINES ANTICANCÉREUSES PAR LE BIAIS DE L'INHIBITION DE FGFR KINASES
    申请人:ASTEX THERAPEUTICS LTD
    公开号:WO2013061081A1
    公开(公告)日:2013-05-02
    The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    这项发明涉及新的喹啉生物化合物,包括含有该化合物的药物组合物,用于制备该化合物的方法以及该化合物在治疗疾病(例如癌症)中的用途。
  • [EN] PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE TRIAZINE, ET LEUR UTILISATION COMME INHIBITEURS D'AXL
    申请人:PFIZER
    公开号:WO2016097918A1
    公开(公告)日:2016-06-23
    Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    公式(I)的化合物: (I) 这些化合物的制备方法,包含这些化合物的组合物,以及这些化合物的用途。
  • SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF
    申请人:Impact Therapeutics (Shanghai), Inc
    公开号:EP3567041A9
    公开(公告)日:2022-04-20
    The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A4, B1-B3, D1-D4 and R1-R3 are defined herein. Compounds having Formula I are kinalse inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.
    本公开涉及取代的融合杂芳香化合物及其用途。具体而言,本公开提供了以下式I的化合物: 或其药用可接受的盐或前药,其中A1-A4、B1-B3、D1-D4和R1-R3如本文所述定义。具有式I的化合物是激酶抑制剂。因此,本公开的化合物可用于治疗由DDR功能缺陷引起的临床状况,如癌症。
  • COMBINATION OF KINASE INHIBITORS AND USES THEREOF
    申请人:INTELLIKINE, LLC
    公开号:US20150030588A1
    公开(公告)日:2015-01-29
    The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.
    本发明提供了一种治疗与PI3-激酶a和/或受体酪氨酸激酶(RTK)有关的疾病状况的方法。另一方面,该发明提供了一种治疗与PI3-激酶α和/或受体酪氨酸激酶(RTK)有关的疾病状况的方法。另一方面,提出了一种抑制细胞中Akt(S473)磷酸化的方法。
  • Direct C–H sulfenylation of quinoxalinones with thiols under visible-light-induced photocatalyst-free conditions
    作者:Qing-Hu Teng、Yan Yao、Wen-Xiu Wei、Hai-Tao Tang、Jia-Rong Li、Ying-Ming Pan
    DOI:10.1039/c9gc03045j
    日期:——

    We have developed a metal-free and catalyst-free visible-light-promoted direct C–H sulfenylation of quinoxalin-2(1H)-ones with thiols for the synthesis of diverse 3-sulfenylquinoxalin-2(1H)-ones.

    我们开发了一种无属、无催化剂的可见光促进的直接C-H砜基化方法,用于合成多样化的3-砜基喹啉-2(1H)-酮。
查看更多